Loading
institutionsInstitution
Peking University Cancer Hospital
Beijing's dedicated cancer hospital and the leading Chinese centre for gastric cancer trials, where claudin 18.2 CAR-T and PD-1 combinations were first tested in gastric disease.
Also called: Beijing Cancer HospitalBeijing Institute for Cancer Research北京大学肿瘤医院
Overview
Founded in 1976 as the Beijing Institute for Cancer Research, the hospital is Peking University's cancer centre and a nationally designated clinical speciality in gastrointestinal oncology, gastric surgery, lymphoma, melanoma and sarcoma. Lin Shen's GI oncology department has led or co-led the pivotal Chinese trials of PD-1 antibodies in gastric and oesophageal cancer, the first-in-human claudin 18.2 CAR-T study (satricabtagene autoleucel with CARsgen), and early ADC programmes. Jun Guo's melanoma group defined the biology and treatment of acral and mucosal melanoma, which dominate in East Asia. The hospital runs a large phase 1 unit and the Beijing cancer registry.
Location
Beijing, CN
Type
cancer center · Peking University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#86 · 42 points (0 Newsweek + 0 NCI + 42 from 21 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to Peking University Cancer Hospital, including child institutions. 1,344 works · 18,195 citations · 66% open access · 21% clinical trials · 1% reviews.
Oncology works per year
3042022
2492023
2712024
2892025
2312026
Most works
- Lu Si68 works
- Lin Shen67 works
- Lili Mao45 works
- Jifang Gong45 works
- Huiping Li43 works
- Xue Bai41 works
- Jun Guo41 works
- Bin Lian40 works
- Nan Li40 works
- Chuanliang Cui40 works
Most cited
- Gastric and oesophageal cancer
- Claudin 18.2 CAR-T
- Acral and mucosal melanoma
- Lymphoma
- Phase 1 unit
Changsong Qi
Associate Professor of GI Oncology, Peking University Cancer Hospital
Gastric cancerCAR-TClaudin 18.2
First author of the CT041 trials that showed a CAR-T can shrink gastric and pancreatic tumours.
Jun Guo
Professor; Department of Renal Cancer and Melanoma, Peking University Cancer Hospital
MelanomaAcral and mucosal melanomaRenal cell carcinoma
Jun Guo built China's melanoma programme around the acral and mucosal subtypes common in Asia, and led the trials that made toripalimab the first domestic PD-1 antibody approved.
Lin Shen
Professor and Director, Department of GI Oncology, Peking University Cancer Hospital
Gastric cancerClaudin 18.2CAR-T for solid tumours
Led the CT041 trials that produced the first CAR-T therapy approved for a solid tumour, in gastric cancer.
Yuqin Song
Vice President
LymphomaHaematologic oncologyNovel agents in B-cell malignancies
Lymphoma specialist and Vice President of Peking University Cancer Hospital.
Ziyu Li
President and Deputy Party Secretary
Gastric cancer surgeryGastrointestinal surgical oncologyMinimally invasive surgery
Gastric cancer surgeon who serves as President of Peking University Cancer Hospital.
Similar pages
- PersonZonghai Li
Shares CARsgen Therapeutics, Satricabtagene autoleucel, Claudin 18.2, CAR-T cell therapy.
- TrialDV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC).
- TrialPerioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC).
- InstitutionRenji Hospital, Shanghai Jiao Tong University
Shares CARsgen Therapeutics, Satricabtagene autoleucel, CAR-T cell therapy, Gastric & gastro-oesophageal junction cancer.
- TrialA Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC).
- TrialA Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC).
- InstitutionChinese Society of Clinical Oncology
Shares Jun Guo, CSCO guidelines (China), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- TrialA Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors.
cancers
fronts
technologies
targets
drugs
ApprovedADC
ApprovedCAR-T (Claudin 18.2)